AstraZeneca in the clear over PLATO
This article was originally published in Scrip
Executive Summary
AstraZeneca has received confirmation from the US Department of Justice that it is closing its investigation into PLATO, the huge pivotal clinical trial that formed the basis of the approval of the anti-clotting drug ticagrelor (Brilinta/Brilique). AstraZeneca says the US government is not planning any further action.